Was the Lexeo Therapeutics (LXEO) CMO’s share sale a discretionary open-market transaction?

The filing explains that the 22,306-share sale was executed to cover tax obligations on the release of performance RSUs. This characterizes the sale as a tax-related disposition rather than a discretionary open-market sale motivated by a change in investment view.

Lexeo Therapeutics (LXEO) CMO awarded 55K shares and sells 22K to cover RSU taxes

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Lexeo Therapeutics Chief Medical Officer Narinder Pal Bhalla reported a compensation-related stock grant and a tax-related share sale. On June 29, 2026, he received 55,000 shares of common stock as a grant or award. On July 1, 2026, 22,306 shares of common stock were sold at a weighted average price of $4.42 per share to cover tax obligations on the release of performance Restricted Stock Units. After these transactions, he directly held 82,194 shares of common stock, including 49,500 RSUs, each representing a contingent right to receive one share.

Insider Trade Summary

Net Seller: 22,306 shares ($98,593)

Net Sell 2 txns

Insider Bhalla Narinder Pal

Role Chief Medical Officer

Sold 22,306 shs ($99K)

Type	Security	Shares	Price	Value
Sale	Common Stock	22,306	$4.42	$99K
Grant/Award	Common Stock	55,000	$0.00	--

Holdings After Transaction: Common Stock — 82,194 shares (Direct, null)

Footnotes (1)

Represents a sale to cover tax obligations on the release of performance Restricted Stock Units ("RSUs"). This transaction was executed in multiple trades at prices ranging from $4.341 to $4.73. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Includes 49,500 RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.

Key Figures

Shares sold for taxes: 22,306 shares Weighted average sale price: $4.42 per share Shares granted: 55,000 shares +3 more

6 metrics

Shares sold for taxes 22,306 shares Sale on July 1, 2026 to cover tax obligations

Weighted average sale price $4.42 per share Tax-related sale of common stock

Shares granted 55,000 shares Common stock grant on June 29, 2026

Shares held after transactions 82,194 shares Direct common stock holdings following reported activity

RSUs included in holdings 49,500 RSUs Each RSU is a contingent right to one share

Sale price range $4.341–$4.73 per share Multiple trades comprising the tax-related sale

Key Terms

Restricted Stock Units ("RSUs"), weighted average sale price, performance RSUs, grant, award, or other acquisition

4 terms

Restricted Stock Units ("RSUs") financial

"Includes 49,500 RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

performance RSUs financial

"Represents a sale to cover tax obligations on the release of performance Restricted Stock Units ("RSUs")."

Performance RSUs are promises to deliver company shares to executives or employees only if the business meets preset goals such as revenue, profit, stock price, or operational targets. They matter to investors because they align management pay with measurable company results and can affect the number of shares outstanding and future earnings per share once the shares are issued. Think of them as a bonus paid in stock that only arrives if the team hits the agreed milestones.

grant, award, or other acquisition financial

"Grant, award, or other acquisition"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/01/2026 - 06:48 PM Accepted by SEC EDGAR 07/01/2026 - 06:48 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bhalla Narinder Pal

(Last)

(First)

(Middle)

C/O LEXEO THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, 6TH FLOOR

(Street)

NEW YORK

10010

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/29/2026		A		55,000	A	$0	104,500	D
Common Stock	07/01/2026		S⁽¹⁾		22,306	D	$4.42⁽²⁾	82,194⁽³⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents a sale to cover tax obligations on the release of performance Restricted Stock Units ("RSUs").

2. This transaction was executed in multiple trades at prices ranging from $4.341 to $4.73. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. Includes 49,500 RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.

	/s/ Youjin Choi, Attorney-in-Fact	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Lexeo Therapeutics (LXEO) report for Narinder Pal Bhalla?

Lexeo’s Chief Medical Officer Narinder Pal Bhalla reported a stock grant of 55,000 common shares and a related sale of 22,306 shares. The sale was executed solely to cover tax obligations on the release of performance RSUs, not as a discretionary open-market divestment.

How many Lexeo Therapeutics (LXEO) shares did the CMO sell and at what price?

Bhalla reported selling 22,306 shares of Lexeo common stock at a weighted average price of $4.42 per share. The filing notes the transaction occurred in multiple trades between $4.341 and $4.73, and was undertaken to cover tax obligations on performance RSUs.

What stock award did the Lexeo Therapeutics (LXEO) CMO receive in this Form 4?

The Form 4 shows Bhalla received a grant of 55,000 shares of Lexeo common stock at no purchase price. This grant is characterized as a compensation-related award, increasing his direct equity position before accounting for shares sold to satisfy tax obligations.

How many Lexeo Therapeutics (LXEO) shares does the CMO hold after these transactions?

Following the reported grant and tax-related share sale, Bhalla directly holds 82,194 shares of Lexeo common stock. This total explicitly includes 49,500 Restricted Stock Units, each representing a contingent right to receive one additional common share in the future.

What are the Restricted Stock Units (RSUs) mentioned in the Lexeo Therapeutics (LXEO) filing?

The filing states that Bhalla’s holdings include 49,500 RSUs, with each RSU representing a contingent right to receive one share of Lexeo common stock. Some of the reported share sales were specifically to cover tax obligations associated with the release of these performance RSUs.